B-cell differentiation immunophenotypes in classical Hodgkin lymphomas

被引:22
|
作者
Bai, M [1 ]
Panoulas, V
Papoudou-Bai, A
Horianopoulos, N
Kitsoulis, P
Stefanaki, K
Rontogianni, D
Agnantis, NJ
Kanavaros, P
机构
[1] Univ Ioannina, Sch Med, Dept Pathol, Fac Med, GR-45110 Ioannina, Greece
[2] Univ Ioannina, Fac Med, Dept Anat Histol Embryol, GR-45110 Ioannina, Greece
[3] Agia Sophia Hosp, Dept Pathol, Athens, Greece
[4] Evangelismos Med Ctr, Dept Pathol, Athens, Greece
关键词
Bc16; CD10; MUM1; CD138; classical Hodgkin lymphomas;
D O I
10.1080/10428190500306784
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The bcl6/CD10/ MUM1/CD138 B-cell differentiation immunophenotypes were analysed in 101 cases of classical Hodgkin lymphomas (cHL) aiming to elucidate their histogenesis. Three major bcl6/CD10/MUM1/CD138 immunophenotypes were distinguished on the basis of the immunohistochemical positivity of Hodgkin and Reed-Sternberg (H/RS) cells: (a) the late germinal center (GC)/ early post-GCB-cell-like immunophenotype (bcl6-/CD10-/MUM1+/CD138-); 59/101 cases (59%), ( b) the post-GCB-cell-like immunophenotype (bcl6-/CD107/MUM1+/CD138+); 24/101 cases (24%) and (c) the indeterminate immunophenotype (bcl6+/ CD107/MUM1+/CD138-: 14 cases and bcl6+/CD107/ MUM1+/CD138+: four cases); 18/ 101 cases (18%). The above findings indicate that H/ RS cells in most cHL display bcl6/CD10/MUM1/CD138 immunophenotypes consistent with late GC/early post-GC or post-GCB-cell differentiation. In addition, H/ RS cells in a small fraction of cHL display indeterminate bcl6/CD10/MUM1/CD138 immunophenotypic profiles which are characterized by simultaneous expression of GC, late GC/early post-GC and post-GCB-cell differentiation proteins. These immunophenotypic profiles do not correspond to the differentiation immunophenotypes of normal B-cells and their identification in a part of cHL suggests that the differentiation process of H/RS cells is not complete in a fraction of these cells and/or is still ongoing at the time of observation.
引用
收藏
页码:495 / 501
页数:7
相关论文
共 50 条
  • [2] Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas
    Miles, R. R.
    Smith, L. B.
    Ogilvie, S.
    Teruya-Feldstein, J.
    Hsi, E. D.
    Elenitoba-Johnson, K. S. J.
    Lim, M. S.
    MODERN PATHOLOGY, 2008, 21 : 265A - 265A
  • [3] Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas
    Miles, R. R.
    Smith, L. B.
    Ogilvie, S.
    Teruya-Feldstein, J.
    Hsi, E. D.
    Elenitoba-Johnson, K. S. J.
    Lim, M. S.
    LABORATORY INVESTIGATION, 2008, 88 : 265A - 265A
  • [4] Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas
    Miles, Rodney R.
    Mankey, Cohra C.
    Seiler, Charlie E., III
    Smith, Lauren B.
    Teruya-Feldstein, Julie
    Hsi, Eric D.
    Elenitoba-Johnson, Kojo S. J.
    Lim, Megan S.
    HUMAN PATHOLOGY, 2009, 40 (12) : 1731 - 1737
  • [5] B-cell non-Hodgkin lymphomas
    Silkenstedt, Elisabeth
    Salles, Gilles
    Campo, Elias
    Dreyling, Martin
    LANCET, 2024, 403 (10438): : 1791 - 1807
  • [6] B-cell non Hodgkin lymphomas in children
    Hatzipantelis, E. S.
    Sidi, V.
    Gombakis, N.
    Venizelos, I.
    Avramidou, K.
    Fragandrea, L.
    Papakonstantinou, E.
    Karakoli, A.
    Koliouskas, D. E.
    PEDIATRIC BLOOD & CANCER, 2007, 49 (03) : 388 - 389
  • [7] Flow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas
    Gajzer, David C.
    Fromm, Jonathan R.
    CANCERS, 2025, 17 (05)
  • [8] Radioimmunotherapy for B-Cell Non-Hodgkin Lymphomas
    Tomblyn, Michael
    CANCER CONTROL, 2012, 19 (03) : 196 - 203
  • [9] Precursors of Hodgkin's disease and B-cell lymphomas
    Manis, JP
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (16): : 1280 - 1282
  • [10] INDUCTION OF DIFFERENTIATION IN MURINE B-CELL LYMPHOMAS
    LANIER, LL
    WARNER, NL
    FEDERATION PROCEEDINGS, 1982, 41 (03) : 425 - 425